2022
DOI: 10.1097/cce.0000000000000772
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Thrombocytopenia in Patients Receiving Percutaneous Mechanical Circulatory Support With an Impella Device

Abstract: OBJECTIVES: Evaluate the time course of thrombocytopenia in patients with Impella devices (Abiomed, Danvers, MA). DESIGN: This was a retrospective, multicenter review of electronic medical records at a large hospital system from April 2018 to August 2020. SETTING: Electronic medical records of patients at SSM Health hospitals were reviewed. PATIENTS: Patients 18–89 years old admitted to an SSM Health hospital from April 2018 to August 2020 who received greater than or equal to 24 hours of percutaneous me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 18 publications
(34 reference statements)
0
2
0
Order By: Relevance
“…The growing body of evidence indicates that shear-mediated quantitative and qualitative platelet dyscrasia is the main driver of MCS bleeding events. Thrombocytopenia defined as platelet count <150,000/μL or 50% less than baseline 5 is observed in up to 86% of MCS patients 7 . Device-related thrombocytopenia has rapid onset, with platelet count declining drastically within 24 hours following device implantation, and persisting until device removal 8 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The growing body of evidence indicates that shear-mediated quantitative and qualitative platelet dyscrasia is the main driver of MCS bleeding events. Thrombocytopenia defined as platelet count <150,000/μL or 50% less than baseline 5 is observed in up to 86% of MCS patients 7 . Device-related thrombocytopenia has rapid onset, with platelet count declining drastically within 24 hours following device implantation, and persisting until device removal 8 .…”
Section: Introductionmentioning
confidence: 99%
“…The growing body of evidence indicates that shear-mediated quantitative and qualitative platelet dyscrasia is the main driver of MCS bleeding events. Thrombocytopenia defined as platelet count <150,000/μL or 50% less than baseline 5 is observed in up to 86% of MCS patients 7 .…”
Section: Introductionmentioning
confidence: 99%